Renuology Wants To Make Personalized Peptide Care More Practical

A medical practice can have access to peptide products, but that does not necessarily mean it has everything needed to build a thoughtful longevity program. Practitioners must also navigate scientific information, patient differences, education, sourcing, and the practical demands of organizing care.

As interest in peptide medicine grows, this gap is becoming an important part of the conversation. The question is shifting from whether peptides are attracting attention to how medical practices can approach them responsibly.

Renuology, a precision wellness company led by CEO and Co Founder Ashlee Kaufman, PA C, MMS, is building its business around that challenge. Through personalized testing, medical grade peptide access, clinician education, and its PeptideRx.Health platform, the company is working to provide infrastructure for practices exploring more individualized approaches to longevity care.

Its larger ambition is not simply to offer another collection of wellness products. Renuology wants to help change how practitioners and patients think about the relationship between scientific information, clinical judgment, and personalized wellness.

“The biggest evolution in wellness isn't another product. It's understanding the person before choosing the product,” Kaufman says.

The Industry Is Asking A More Important Question

The popularity of peptides has created a new level of interest in longevity medicine. For healthcare practices, however, entering this space involves more than selecting products from a supplier.

Practitioners may need to evaluate scientific literature, understand the distinctions between different compounds, organize relevant resources, and determine how education fits into their existing clinical processes.

This is where Renuology sees an opportunity.

The company believes that longevity care should begin with the individual patient rather than a standard menu of products. A patient's circumstances, available information, and clinical needs should be considered before a practitioner discusses a potential approach.

That philosophy challenges a familiar pattern in wellness: choosing a product first and asking questions later.

Renuology's approach places those questions at the beginning.

Its work is focused on helping practitioners access information and tools that may support more informed decision making. The company does not position peptides as products that consumers should blindly select or use without appropriate professional oversight.

For Kaufman, this is part of a broader change she wants to see across the industry.

“I don't want Renuology to be known as another peptide or supplement company,” she says. “I want us to be known as a company that helped change the conversation from ‘What should I take?’ to ‘What does my body actually need?’”

A Founder Who Has Seen The Industry From Multiple Angles

Kaufman’s approach to Renuology is shaped by nearly three decades of experience in health and wellness, clinical medicine, product development, entrepreneurship, and business leadership.

Her career includes co-founding and successfully exiting an e-commerce company during the early dot-com era. She has held leadership roles with global wellness brands and formulated more than 150 nutritional products, including four patented products.

These experiences have given her a broad perspective on the health and wellness industry, from products and businesses to clinical environments and the people who use them.

Her connection to the mission is also deeply personal. After losing her brother to Type 1 Diabetes, Kaufman’s perspective on health changed. The experience strengthened her belief that people deserve better information about their bodies and access to practitioners who can help them make informed decisions.

That belief became part of the foundation of Renuology.

Today, the company brings together a leadership team with more than 100 years of combined experience across clinical medicine, pharmaceutical development, formulation, and health innovation, according to company-supplied information.

For Kaufman, Renuology represents the intersection of her professional experience and personal commitment to informed wellness.

What DNA Testing Can Add To The Conversation

One of Renuology’s initiatives is its Peptide DNA testing platform, designed to provide healthcare practitioners with genetic insights that may help inform individualized wellness strategies and peptide conversations.

The platform reflects a central idea behind precision wellness: the individual should be considered before a standard protocol is selected. Genetic information can provide additional context, but it does not independently determine medical needs or guarantee how someone will respond to a peptide. Interpretation requires appropriate expertise and consideration alongside other relevant clinical information.

Renuology’s practitioner-focused approach is intended to support this broader process. The company is also expanding its DNA platform into areas including methylation, metabolic health, nutrition, performance, hormones, brain health, and overall wellness.

This expansion reflects Renuology’s interest in understanding individuals through multiple areas of information rather than relying on one product or measurement. For practices, the goal is to make personalized wellness conversations more informed and organized.

PeptideRx.Health Connects The Tools Practices Need

Testing is only one part of Renuology’s strategy. The company is also developing PeptideRx.Health, a platform designed to bring dosing tools, protocol organization, science, education, and training into one ecosystem.

The platform addresses a practical challenge for practitioners exploring peptide medicine: information and resources can be spread across multiple sources, making organization and ongoing education important to implementation.

PeptideRx.Health is intended to bring these elements together in a structured environment. Its focus includes dosing tools, protocol organization, scientific information, and clinician education, providing resources to support practitioners navigating the evolving field of peptide medicine.

The platform does not replace clinical judgment or establish that a particular peptide, dose, or protocol is appropriate for every patient. Instead, Renuology positions it as infrastructure supporting informed practitioner decision-making.

That distinction is central to the company’s identity: providing access to peptide products alongside the resources and education needed to approach the field responsibly.

Responsible Innovation Requires More Than Enthusiasm

Peptides have generated excitement across the wellness industry, but Renuology believes responsible growth requires more than enthusiasm.

The company emphasizes medical oversight, education, and clear boundaries around peptide-related decisions. It states that it works with healthcare practitioners rather than encouraging consumers to independently select peptide products.

Renuology also says its peptides undergo rigorous testing and are sourced through a quality-focused process. These are company-stated commitments and should not be interpreted as proof that every product is FDA approved or that every peptide has established clinical benefits.

For practices, responsible implementation requires understanding the difference between scientific interest, product availability, and proven medical application.

Kaufman believes the next stage of peptide medicine should focus on becoming more informed and precise. “Peptides are incredibly exciting, but the future isn't simply about having access to more therapies,” she says. “It's about becoming smarter and more precise about how we approach the individual.”

Renuology Recognized For Peptide Innovation

Renuology has also received recognition from Evergreen Awards, which named the company the Best Peptide Innovation Company in Juno Beach, Florida of 2026. The recognition highlights Renuology’s focus on personalization, practitioner education, genetic insights, peptide science, testing, and person-first wellness. Led by CEO and Co-Founder Ashlee Kaufman, PA-C, MMS, Renuology was recognized for bringing greater structure and individualized thinking to the evolving peptide and longevity landscape. The award reflects its broader precision wellness approach and does not independently assess clinical effectiveness or safety.

The Larger Mission: Helping Practices Build For Longevity Medicine

Renuology’s ambition extends beyond peptides. The company aims to help practices participate in the evolving field of longevity medicine through stronger infrastructure, education, and personalized resources.

Its work across DNA testing, practitioner education, peptide-related resources, and PeptideRx.Health reflects an effort to connect the different elements of a more organized approach to wellness and longevity care.

Ashlee Kaufman’s professional background contributes to that vision. Her experience as a clinician, entrepreneur, product formulator, and business leader gives her a broad perspective on opportunities and challenges within the wellness industry. Her personal experience with chronic disease also informs the company’s mission.

“For decades, wellness has asked people to fit into protocols,” Kaufman says. “I believe the next generation of wellness will build protocols around the person.”

That belief is central to Renuology’s approach: helping practitioners better understand the individual before discussing products, protocols, or wellness strategies.

Explore The Future Of Personalized Peptide Care

Medical practices and healthcare professionals interested in the evolving field of peptide medicine can learn more about Renuology through renuology.com. Readers can also explore the company's work through Instagram, Facebook, and LinkedIn.

Renuology’s PeptideRx.Health platform provides resources for dosing tools, protocol organization, science, education, and training. As peptide care evolves, Renuology focuses on building infrastructure that helps practitioners approach each individual with greater care, context, and information. For Ashlee Kaufman, the future of wellness starts with asking better questions before choosing.

About Renuology

Renuology is a precision wellness company focused on a personalized approach to health and longevity. The company combines DNA insights, evidence-based peptides, clinical research, practitioner education, and PeptideRx.Health to support more informed wellness decisions. Renuology is led by CEO and Co-Founder Ashlee Kaufman, PA-C, MMS.

Disclaimer: This article is for informational purposes only and is not intended to promote, encourage, or provide professional advice related to peptide medicine, genetic testing, or personalized healthcare. Always consult a qualified healthcare professional before using peptides, undergoing genetic testing, or making decisions related to medical treatments.